Skip to main content
. 2022 Apr 29;13:20406207221093964. doi: 10.1177/20406207221093964

Figure 2.

Figure 2.

Intensive chemotherapy-based induction and consolidation regimens incorporating venetoclax for the treatment of AML.

*peg-filgrastim permitted to replace filgrastim on D5 (induction) or D3 (consolidation).

ψ venetoclax administered at varying dosage by cohort (A: 50 mg, B: 100 mg, C: 200 mg, D: 400 mg, E: 600 mg).